Fmr LLC trimmed its holdings in Bruker Co. (NASDAQ:BRKR) by 0.4% during the second quarter, HoldingsChannel.com reports. The firm owned 7,430,445 shares of the medical research company’s stock after selling 29,240 shares during the quarter. Fmr LLC’s holdings in Bruker were worth $215,779,000 at the end of the most recent quarter.
Several other large investors have also made changes to their positions in the company. BlackRock Inc. lifted its stake in shares of Bruker by 1.7% in the 2nd quarter. BlackRock Inc. now owns 5,358,747 shares of the medical research company’s stock valued at $155,618,000 after purchasing an additional 91,058 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of Bruker by 0.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 961,131 shares of the medical research company’s stock valued at $27,912,000 after purchasing an additional 2,606 shares during the period. Allianz Asset Management GmbH lifted its stake in shares of Bruker by 215.1% in the 1st quarter. Allianz Asset Management GmbH now owns 955,177 shares of the medical research company’s stock valued at $28,578,000 after purchasing an additional 652,032 shares during the period. Fuller & Thaler Asset Management Inc. lifted its stake in shares of Bruker by 40.4% in the 2nd quarter. Fuller & Thaler Asset Management Inc. now owns 778,096 shares of the medical research company’s stock valued at $22,596,000 after purchasing an additional 223,856 shares during the period. Finally, Schwab Charles Investment Management Inc. lifted its stake in shares of Bruker by 7.7% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 667,122 shares of the medical research company’s stock valued at $19,374,000 after purchasing an additional 47,728 shares during the period. 64.83% of the stock is currently owned by institutional investors.
BRKR has been the topic of a number of recent analyst reports. Morgan Stanley dropped their price objective on Bruker from $31.00 to $29.00 and set an “equal weight” rating on the stock in a research note on Friday, July 13th. Zacks Investment Research lowered Bruker from a “hold” rating to a “sell” rating in a research report on Tuesday, July 24th. BidaskClub raised Bruker from a “hold” rating to a “buy” rating in a research report on Friday, August 24th. ValuEngine lowered Bruker from a “buy” rating to a “hold” rating in a research report on Friday, September 21st. Finally, UBS Group initiated coverage on Bruker in a research report on Tuesday, October 9th. They issued a “sell” rating and a $30.00 target price for the company. They noted that the move was a valuation call. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and one has given a buy rating to the stock. Bruker presently has an average rating of “Hold” and a consensus target price of $33.90.
Shares of Bruker stock opened at $32.32 on Friday. Bruker Co. has a one year low of $28.13 and a one year high of $36.53. The stock has a market capitalization of $4.86 billion, a P/E ratio of 26.71, a PEG ratio of 1.98 and a beta of 1.34. The company has a debt-to-equity ratio of 0.26, a current ratio of 2.22 and a quick ratio of 1.27.
Bruker (NASDAQ:BRKR) last issued its earnings results on Thursday, November 1st. The medical research company reported $0.37 EPS for the quarter, beating analysts’ consensus estimates of $0.30 by $0.07. Bruker had a return on equity of 27.03% and a net margin of 4.99%. The business had revenue of $466.60 million during the quarter, compared to analyst estimates of $451.88 million. During the same period in the previous year, the company posted $0.29 EPS. The firm’s revenue was up 7.1% compared to the same quarter last year. Analysts expect that Bruker Co. will post 1.38 EPS for the current fiscal year.
Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry systems; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.
See Also: Why do corrections happen?
Want to see what other hedge funds are holding BRKR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bruker Co. (NASDAQ:BRKR).
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.